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ABSTRACT 
Quantitative ultrasound of the heel captures heel bone properties that independently predict 
fracture risk and, with bone mineral density (BMD) assessed by x-ray (DXA), may be 
convenient alternatives for evaluating osteoporosis and fracture risk. We performed a meta-
analysis of genome-wide association (GWA) studies to assess the genetic determinants of 
heel broadband ultrasound attenuation (BUA, n=14,260), velocity of sound (VOS, n=15,514) 
and BMD (n=4,566) in 13 discovery cohorts. Independent replication involved 7 cohorts with 
GWA data (in silico n=11,452) and new genotyping in 15 cohorts (de novo n=24,902). In 
combined random effects meta-analysis of the discovery and replication cohorts, 9 SNPs had 
genome-wide significant (p<5×10-8) associations with heel bone properties. Alongside SNPs 
within or near previously identified osteoporosis susceptibility genes including ESR1 
(6q25.1: rs4869739, rs3020331, rs2982552), SPTBN1 (2p16.2: rs11898505), RSPO3 
(6q22.33: rs7741021), WNT16 (7q31.31: rs2908007), DKK1 (10q21.1: rs7902708), and 
GPATCH1 (19q13.11: rs10416265), we identified a new locus on chromosome 11q14.2 
(rs597319 close to TMEM135, a gene recently linked to osteoblastogenesis and longevity) 
significantly associated with both BUA and VOS (p<8.23×10-14). In meta-analyses involving 
25 cohorts with up to 14,985 fracture cases, six of 10 SNPs associated with heel bone 
properties at p<5×10-6 also had the expected direction of association with any fracture 
(p<0.05), including 3 SNPs with p<0.005: 6q22.33 (rs7741021), 7q31.31 (rs2908007), and 
10q21.1 (rs7902708). In conclusion, this GWA study reveals the effect of several genes 
common to central DXA-derived BMD and heel ultrasound/DXA measures and points to a 
new genetic locus with potential implications for better understanding of osteoporosis 
pathophysiology.  
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INTRODUCTION 
Bone structure in vivo has largely been evaluated using the attenuation of a photon beam by 
hydroxyapatite, the principle mineral in bone. This is positively related to the mass of 
hydroxyapatite in the path of the beam conventionally termed bone mineral content and 
normalised to bone area to produce an entity termed areal bone mineral density (BMD).  To 
allow for the reduced attenuation of the beam by overlying non-bone tissues in central areas 
of the body, two photon beam energies are used, resulting in a clinical technique termed dual-
energy X-ray absorptiometry (DXA), which at peripheral skeletal sites is termed pDXA. 
Over the past 60 years, ultrasonic material analysis has been developed as a method of 
determining material properties of a variety of structures. In the last 30 years this 
methodology has been applied to the in vivo assessment of bone structure and fragility termed 
Quantitative Ultrasound (QUS). This consists of the use of two separate ultrasound 
measurement techniques, velocity of sound (VOS) and bone ultrasound attenuation (BUA). 
While much remains to be discovered about the exact physical determinants of quantitative 
ultrasound (QUS) measures in the intact living calcaneum (1), cadaver studies have 
established a strong correlation of such indices with bone quantity and trabecular structure 
(2). Assessment of bone properties in the heel using QUS can predict the risk of prevalent 
osteoporotic fractures, such as those in the spinal vertebrae, comparably with DXA of the 
spine or hip, the so-called gold standard clinical techniques (3-5). Pearson correlation 
coefficients of heel QUS or pDXA with central DXA of the hip or spine in population-based 
studies are modest, typically in the range 0.4-0.6 (6). Moreover, twin- and family-based 
studies have found genetic correlations of the order of 0.3-0.6 and environmental correlations 
of the order of 0.1-0.3 (7-9); yet relative risk estimates for fracture using QUS are of similar 
magnitude to those derived from central DXA (5,10,11). A recent meta-analysis showed that 
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heel QUS predicts risk of various fractures (hip, vertebral, and any clinical fractures) 
independently from hip BMD (12). Overall, these results suggest that QUS of the calcaneum 
might capture additional genetic determinants of bone structure beyond those associated with 
central DXA. 
 A genetic contribution to osteoporosis is well established with heritability estimates reaching 
84% for central BMD (13), 74% for heel QUS (7,14), 47% for bone loss (15), and 48% for 
hip fracture (16). Previous genome-wide association (GWA) studies have identified several 
chromosomal regions associated with BMD in the hip and lumbar spine regions (17,18). The 
most recent meta-analysis of GWA studies, performed in the context of the Genetics Factors 
for Osteoporosis (GEFOS) consortium, identified 56 genome-wide significant loci (32 new) 
associated with hip/spine BMD (19). Fourteen out of these 56 BMD-associated loci were also 
associated with fracture risk in a case-control meta-analysis involving about 31,000 fracture 
cases among 133,000 individuals (19). Using data from the GEFOS consortium, we aimed to 
extend the findings for central DXA-derived BMD phenotypes by searching for single 
nucleotide polymorphisms (SNPs) associated with heel QUS or heel DXA measures across 
the human genome. 
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RESULTS 
Key features of the discovery and replication phases are summarised in Figure 1. In 
aggregate, the initial discovery phase meta-analysis in 11 cohorts (Supplementary Table 1) 
identified 42 loci of at least suggestive significance in relation to heel bone measures, of 
which 9 overlapped with loci previously found to be potentially associated with hip or spine 
BMD in the GEFOS-BMD meta-analysis (19). Regional conditional analyses results were 
available for QUS measures from 9 cohorts (comprising 7 of the initial discovery cohorts and 
a further 2 new cohorts that joined later). Based on the results of the conditional analyses 
(that identified two secondary signals for the QUS measures) and final combined meta-
analysis of the unconditional results from all 13 discovery cohorts, a total of 25 independent 
SNPs were selected for replication in the next phase (i.e. in silico studies and de novo 
genotyping). Including the two secondary signals, the selected SNPs comprised 15 SNPs that 
were primarily associated with either BUA or VOS, and 12 SNPs that were associated with 
heel DXA BMD (Table 2).  
Associations between the 15 SNPs that were considered for replication primarily on the basis 
of their association with heel BUA or VOS are shown in Figure 2. The SNP characteristics 
are summarized in Table 2. In the combined meta-analysis of the discovery and replication 
cohorts using a random-effects model, 9 SNPs showed genome-wide significant associations, 
of which 7 were previously reported to be associated with central DXA BMD (19). Two of 
the SNPs (rs7741021 and rs2908007) also showed genome-wide significant association with 
heel DXA BMD (Table 2). Three SNPs on chromosome 6q25.1 (rs4869739, rs3020331, 
rs2982552) mapped to intronic or regulatory regions around the ESR1 (estrogen receptor 1) 
and CCDC170 (coiled-coil domain containing 170, previously known as C6orf97) genes 
(Figure 3), and 5 other SNPs mapped to loci within or near previously identified osteoporosis 
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susceptibility genes, including 2p16.2 (SPTBN1, rs11898505); 6q22.33 (RSPO3, rs7741021); 
7q31.1 (WNT16, rs2908007); 10q21.1 (DKK1, rs7902708); and 19q13.11 (GPATCH1, 
rs10416265). We identified a new locus on chromosome 11q14.2 (TMEM135, rs597319) 
significantly associated with both BUA and VOS (p < 8.23 × 10-14).  
Subsidiary comparisons with fixed-effect meta-analysis results (Supplementary Table 2, 
Supplementary Figure 2, and Supplementary Figure 3) suggested two additional genome-
wide significant loci; one at 7p14.1 upstream of EPDR1 (rs6974574, p < 4.92 × 10-8 for BUA 
and VOS) and the other at 13q14.11 upstream of AKAP11 (rs9533090, p = 5.33 × 10-8 for 
VOS), although there was statistically significant between-study heterogeneity in these two 
loci for the respective phenotypes (Supplementary Table 3), necessitating some caution in 
generalizing the fixed-effect meta-analysis results. Figure 4 provides a comparison of the 
magnitudes of association of the 25 SNPs with heel bone measures and central DXA BMD, 
suggesting generally concordant associations in the overlapping genome-wide significant or 
suggestive loci.  
We further tested if the genome-wide significant or suggestive genetic loci were associated 
with fracture risk based on data available from 25 cohorts with up to 54,245 participants, 
among whom there were 14,958 cases of any fracture (excluding fractures of the skull and 
extremities i.e. fingers and toes), 10,663 non-vertebral fractures, and 3,220 clinical vertebral 
fractures (Supplementary Table 4). Ten out of ten SNPs associated with heel bone 
properties at p < 5×10-6 showed the expected directions of association with any fracture 
outcome based on the point estimates (Figure 5). Furthermore, 6 of these 10 SNPs showed 
nominally significant (p < 0.05) associations with fractures, including 3 SNPs with p < 0.005 
(i.e. corrected for multiple comparisons using Bonferroni method) at 6q22.33 (rs7741021), 
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7q31.31 (rs2908007), and 10q21.1 (rs7902708). Fixed-effect meta-analysis gave similar 
results (Supplementary Figure 4). 
Supplementary Figure 5 presents forest plots of the study-specific results and summary 
estimates by random effects meta-analysis for the 15 SNPs that were considered for 
replication primarily on the basis of their association with heel BUA or VOS in GWA 
discovery meta-analysis, suggesting generally consistent results across cohorts for a majority 
of the SNPs. Supplementary Figure 6 shows the regional association plots within a one 
megabase window of the top SNP in each locus in the GWA discovery meta-analysis, 
demonstrating strong credible association signals for a number of SNPs underlying the loci 
selected for replication. 
Subsidiary investigation of potential sex differences in the association of SNPs and heel BUA 
or VOS measures did not reveal convincing evidence of potentially important differences, 
considering the secondary nature of the hypothesis and multiple comparisons done 
(Supplementary Figure 7).  
11 
 
DISCUSSION 
This is the first large-scale collaborative GWA study for heel bone properties assessed by 
quantitative ultrasound and DXA of the heel. Its conception was inspired by the observational 
evidence of association of heel QUS measures and fracture risk (12), independent of central 
DXA BMD measures (20), demonstration of a reasonably high genetic heritability of heel 
QUS measures (7), and suggestions of pleiotropic effects of genes in the determination of 
bone phenotypes (8). Indeed, consistent with the expected similarities and differences in the 
physical properties of bone determined by DXA and QUS and prior evidence of moderate 
genetic correlations between the measures (7-9), we found evidence for some genetic loci 
common to heel QUS measures and central DXA BMD as well as a novel locus for heel QUS 
at 11q14.2 (TMEM135, rs597319) that had not been previously identified as associated with 
BMD or other bone phenotype. 
Seven out of 9 genome-wide significant loci found in the present study were previously 
reported to be associated with BMD of the hip and/or spine (Figure 4). This complements 
our previous findings (17-19) and lends support to the hypothesis of partially shared genetic 
determinants between QUS and BMD measures (7-9). A comparison of the standardised 
effect sizes (Figure 4) also revealed existence of some quantitative differences for some 
SNPs. For example, in the 7q31.31 locus (WNT16), the effect of rs2908007 on heel measures 
was about 3 times as great as its effect on hip or spine BMD, supporting Karasik et al.’s 
finding that there is significant pleiotropy in the effects of genes on bone phenotypes at 
different measurement sites (8). Similar quantitative differences were also observed for 
rs7741021 at the 6q22.33 locus (RSPO3). In the absence of bias and assuming minimal type 
II errors (i.e. adequate power), such quantitative differences in effect sizes of SNPs at 
different skeletal sites might indicate heterogeneity in genetically mediated responses of the 
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skeleton to environmental stimuli, including for example, ground reaction forces that are 
particularly high at the heel but are dampened at more proximal sites such as the lumbar spine 
(21,22).  
Perhaps the most intriguing finding was that we  identified a new locus for bone phenotypes 
on chromosome 11q14.2 (rs597319) near the transmembrane protein 135 (TMEM135) gene, 
that was genome-wide significant for both BUA and VOS. The TMEM135 gene was first 
identified in a human lung adenocarcinoma cell line cDNA library (23). It has been suggested 
that it is critically involved in the process of osteoblastogenesis from human multi-potent 
adipose tissue-derived stem cells (24). Marrow fat cells and osteoblasts share a common 
stromal precursor and there is currently great interest in the role of increased marrow fat in 
osteoporotic conditions and the metabolic inter-relationships between these neighbouring cell 
types (25). In-depth protein sequence analysis showed that TMEM135 is a multi-
transmembrane protein with 7 transmembrane helices of high confidence. Homologies exist 
between TMEM135 and the transmembrane region of frizzled-4 (24), a known component of 
the Wnt signaling pathway (26). ENCODE project (27) data shows that 2 SNPs in the 
intronic region of TMEM135 and close to our lead signal (rs502580 and rs603140, both with 
high linkage disequilibrium with rs597319 [>0.92], and both highly associated with QUS 
outcomes in our discovery cohorts [P ~ 1.3E-07 for both]) are associated with changes in 
MIF-1 and Cart1 motifs in osteoblastic cell lines. Interestingly, both of these transcription 
factors have been previously shown to be associated with skeletal development and bone 
density (28,29). Furthermore, TMEM135 was previously reported to be associated with 
longevity in C. elegans models (30) as well as with longevity and walking speed in humans 
(31). In summary, the associations observed in our study might be the results of direct effects 
of increased osteoblastogenesis on heel bone properties, or indirect effects mediated through 
increased mechanical loading of the calcaneum, associated with faster movements. 
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The other genetic loci with significant associations with heel bone measures have previously 
been reported to be associated with BMD or fractures. The ESR1 gene has been shown to be 
related to osteoporosis susceptibility in both candidate gene (32) and GWA studies (18,33). 
SNPs in SPTBN1 gene were significantly associated with central DXA BMD in a previous 
meta-analysis of GEFOS cohorts (18), as were SNPs in WNT16, DKK1, and GPATCH1 genes 
in the recent GEFOS-BMD meta-analysis (19). The RSPO3 gene has recently been suggested 
as a bone-related locus by a GWA study of extreme low and high BMD populations (34). The 
spectrin, beta, non-erythrocytic 1 (SPTBN1) gene located at chromosome 2p16.2 codes for 
the β-subunit of spectrin, which is a molecular scaffold protein essential in linking plasma 
membrane to the actin cytoskeleton. Spectrin plays an important role in determination of cell 
shape, positioning of trans-membrane proteins, resilience of membranes to mechanical stress, 
and organization of organelles and molecular traffic in cells. β-subunits coded by SPTBN1 are 
responsible for most of the spectrin binding activity. Despite several GWA studies 
confirming the association between SPTBN1 and osteoporosis (18,19,33,35), its role in bone 
pathophysiology is unclear. 
The estrogen receptor 1 (ESR1) gene located at chromosome 6q25.1 codes for the estrogen 
receptor type 1 (also known as ER-α). Two isoforms of estrogen receptors in humans (α and 
β) are encoded by two different genes (ESR1 and ESR2) and have distinct tissue and cell 
patterns of expression. Estrogen receptor is a DNA-binding transcription factor that regulates 
the activity of many different genes. Estrogen is well known to inhibit bone resorption 
through both direct and indirect actions on osteoclasts, and it is a major anabolic steroid in 
bone, particularly evident in the establishment of peak bone mass. Postmenopausal bone loss 
is complex, involving many genetically regulated processes. After menopause, bone is lost 
rapidly but variably for several years by most women as osteoclastic bone resorptive activity 
increases in association with osteocyte apoptosis (36). In an osteoporosis GWA study by 
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deCODE Genetics in 2008 (33), several markers close to ESR1 were reported to show 
association with BMD, including intronic variants and upstream SNPs close to CCDC170 
(previously known as C6orf97). This association was replicated in both GEFOS-BMD meta-
analyses (18,19), and we found three independent SNPs in this region associated with heel 
BUA and VOS. Most recently, this locus has been shown to be more associated with cortical 
volumetric BMD (as opposed to trabecular BMD), which implies a role of ESR1 products in 
osteoblastogenesis and cortical porosity (37).  
The wingless-type MMTV integration site family, member 16 (WNT16) gene located at 
chromosome 7q31.31 is part of the Wnt/LRP pathway, which is a known major anabolic 
pathway in bone (38). The effects of activation of this pathway include differentiation of 
mesenchymal precursors into osteoblasts, osteoblast proliferation, bone mineralization, and 
avoidance of osteoblast apoptosis, and inhibition of osteoclastogenesis through effects on 
expression of OPG and RANKL. Other members of this pathway such as LRP5, LRP4, SOST, 
WLS, DKK1 and CTNNB1 have previously been associated with BMD at genome-wide 
significance level (18,19,33,35). 
The variant rs7902708 on chromosome 10q21.1 locates between the MBL2 and DKK1 genes, 
and is in close linkage disequilibrium with another SNP in this locus (rs1373004, R2 = 0.87 in 
HapMap CEU population) that was previously found to have a significant association with 
BMD and fracture risk in GWA meta-analyses (19). Since the MBL2 (mannose-binding lectin 
2) gene product is active in the innate immune system, it is more likely that these variants 
have a cis regulatory effects on Dickkopf-1 (DKK1), which is a known Wnt signalling 
pathway inhibitor (39). Several functional studies have showed the role of DKK1 in osteolytic 
bone lesions in patients with advanced multiple myeloma (40) and its inverse relationship 
with bone mass has been shown in knockout mouse models (41). A similar relationship to the 
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Wnt signalling pathway has also been proposed for the RSPO3 gene (21). Although 
GPATCH1 was also found to be associated with hip and spine BMD in a previous GEFOS 
meta-analysis (19), there is no functional information about it in genomic databases. 
Caution must be exercised in interpreting the results of the heel DXA BMD analyses because 
there were fewer than 7,000 participants contributing to the combined meta-analysis. The 
obtained results, however, were consistent with the work of Portero et al. suggesting that heel 
DXA BMD and BUA measure comparable properties of the calcaneum, which reflect the 
amount of bone mineral in the field of view of the detector (2).   
While the current study had limited statistical power in the meta-analysis of SNP associations 
with fracture outcomes, it was nevertheless encouraging to observe nominally statistically 
significant and expected directions of associations with fractures for 6 SNPs associated with 
heel bone measures, including 3 SNPs at 6q22.33 (rs7741021), 7q31.31 (rs2908007), and 
10q21.1 (rs7902708) whose p-values for association surpassed the multiple testing chance-
corrected threshold of p < 0.005. The concordant findings may, albeit indirectly, suggest that 
some of the genetic susceptibility to fracture could partly be mediated through bone 
properties (e.g. structural or material) captured by QUS or DXA measures; but larger well-
powered studies are needed to appropriately assess such relevance.  
In conclusion, the present GWA study reveals the effect of several genes common to central 
DXA-derived BMD and heel ultrasound/pDXA measures and points to a new genetic locus 
with potential implications for better understanding of osteoporosis pathophysiology. 
Quantitative differences seen in the standardised effect sizes of some SNPs at different 
skeletal sites are potentially indicative of heterogeneity in genetically mediated responses of 
the skeleton to environmental stimuli, including ground reaction forces that are particularly 
high at the heel than at central sites. 
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MATERIALS AND METHODS 
Study subjects and measurements 
The GEFOS consortium is an international collaboration of investigators dedicated to identify 
the genetic determinants of osteoporosis (http://www.gefos.org/). In particular, the GEFOS 
consortium extended the breadth of its predecessor, the Genetic Markers for Osteoporosis 
(GENOMOS) consortium, into meta-analysis of GWA discovery studies. In the current 
GEFOS/GENOMOS project we performed GWA discovery and replication of genetic loci 
associated with heel bone properties, including QUS (measures: Broadband Ultrasound 
Attenuation [BUA] and Velocity of Sound [VOS]) and DXA (measure: heel BMD). 
The discovery phase comprised 13 cohort studies with GWA data and relevant heel bone 
phenotypes (including BUA in 14,260 participants from 9 cohorts; VOS in 15,514 
participants from 9 cohorts; and heel DXA BMD in 4,556 participants from 3 cohorts) arising 
from populations across North America, Europe, and East Asia.  Independent replication was 
performed using summary results from 7 cohorts with GWA data (in silico n=11,452) and 
analysis of individual-level data from 15 other cohorts in the GENOMOS consortium that 
were centrally genotyped for candidate polymorphisms by the Kbioscience laboratory in the 
UK (de novo n=24,902). Characteristics of the study cohorts are summarized in Table 1. All 
studies were approved by institutional ethics review committees at the relevant organizations 
and all participants provided written informed consent. Further descriptive information about 
the participating cohorts is available from the GEFOS/GENOMOS websites 
(http://www.gefos.org/?q=studies and http://www.genomos.eu/index.php?page=cohorts). 
Genotyping and imputation methods 
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All the discovery cohorts were genotyped using commercially available Affymetrix 
(Affymetrix Inc., Santa Clara, CA, USA) or Illumina (Illumina Inc., San Diego, CA, USA) 
genotyping arrays. Quality control was performed independently for each study according to 
standard manufacturer protocols and within study procedures. To facilitate meta-analysis, 
each group performed genotype imputation with IMPUTE or MACH software using 
genotypes from the HapMap Phase II release 22, NCBI build 36 (CEU or CHB/JPT as 
appropriate) as reference panels. Each imputation software estimates an overall imputation 
quality score for each SNP. These quality scores and minor allele frequencies for up to ~2.5 
million SNPs available from each cohort were considered in the meta-analysis. 
Association analyses  
In the discovery phase, each cohort conducted analyses according to a standard pre-specified 
analysis plan under an additive (i.e. per allele) genetic model. Phenotypes for the association 
analyses were defined as the sex-specific standardized residuals from linear regression of 
each outcome variable (BUA, VOS, or heel BMD) on age, age-squared, weight, height, and 
machine type (if more than one machine was used). The assumption of normality of residuals 
in the linear regression model was checked within each cohort for each phenotype and no 
deviations were reported. The SNP-phenotype associations in each study were adjusted for 
potential confounding by population substructure using principal components as appropriate; 
pedigree and twin-based studies – additionally – corrected for family structure. The final 
results submitted to the coordinating centre for meta-analysis were the per-allele regression 
coefficients with corresponding standard errors and p-values for the associations of up to 2.5 
million SNPs and standardized residuals of each outcome variable. Analysis of imputed 
genotypes used either the dosage information from MACH or the genotype probabilities from 
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IMPUTE. The replication analyses used the same analytical procedures as above where 
applicable (e.g. using study-specific standardized residuals as outcomes). 
Meta-analysis 
Meta-analysis of the GWA discovery summary results was conducted in two independent 
collaborating centres (Cambridge, UK, and Boston, USA). Because of potentially limited 
power to detect sex-specific associations, we pre-specified the primary analyses to involve 
meta-analysis of the pooled data (i.e., males and females combined). Quality control filters 
applied for exclusions of SNPs from the meta-analysis were: imputation quality score < 0.3 
for MACH and < 0.4 for IMPUTE, average minor allele frequency of <1% across studies, 
and SNPs missing from >50% of the cohorts contributing to each outcome. Inverse-variance 
fixed-effects meta-analysis (using METAL software) was conducted in the discovery set with 
double genomic correction (42) to control for potential inflation of the test statistics in 
individual studies and in the meta-analysis. The genome-wide level of statistical significance 
was set at p < 5×10-8 and suggestive level of significance at 5×10-8 ≤ p < 5×10-6. There were 
no extreme genomic inflation factors noted in the discovery phase studies or in the GWA 
meta-analysis (Supplementary Table 1). QQ-plots for the combined GWAS meta-analysis 
results are provided in Supplementary Figure 1. 
To help refine the choice of SNPs to be taken forward for replication, conditional analyses 
were conducted within a one megabase window of the best-associated SNP in each locus in 
the discovery cohorts, if there was more than one SNP with a suggestive level of significance. 
These secondary analyses took the SNP in the locus with the lowest p-value and conditioned 
the analysis of all of the other SNPs in the locus by including it in the regression models. In 
addition, for loci containing SNPs previously associated with hip or spine BMD in GEFOS 
(19), we performed additional conditioning on the nearby “BMD SNP”.  
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The DerSimonian and Laird random-effects model was used for meta-analysis of studies in 
the replication set and also in the final combined analysis of the discovery and replication 
studies (43). For each SNP included in the replication phase, we meta-analyzed its 
association with all three phenotypes, simply for completeness, but interpreted the findings 
while taking into account the primary outcome that the SNP was associated with in the 
discovery phase. Fixed-effect meta-analysis results were used for subsidiary comparison. We 
also conducted meta-analysis of the associations of SNPs with fracture outcomes, using only 
SNPs that were associated with BUA, VOS, or heel DXA BMD at p < 5 x 10-6 in the 
combined analyses, to assess their potential relevance to this clinical outcome. 
 
SUPPLEMENTARY MATERIAL 
Supplementary Material is available at HMG online and the GWAS meta-analysis results are 
made available at the GEFOS website (http://www.gefos.org/?q=content/data-release). 
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Table 1. Characteristics of studies that contributed to GWAS discovery and replication of SNP-associations with heel QUS/DXA BMD measures. 
 
Stage\  Demographics Heel QUS/DXA BMD outcomes 
Cohort Country N Females Age (yrs) Weight (kg) Height (cm) BUA (dB/MHz)  VOS (m/s) Heel BMD (g/cm2) 
     (%) Mean (SD) Mean (SD) Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) 
GWAS Discovery                
EPIC UK 2630 56% 62.1 (8.6) 80.5 (15.4) 167 (9) 2630 83 (19) 2630 1632 (40) - - 
FHS USA 3229 58% 64.6 (11.9) 76.8 (17.2) 166 (10) 3229 73 (21) 3225 1548 (38) - - 
HKOS China 730 100% 48.7 (15.4) 54.8 (10.4) 155 (7) 730 74 (22) 730 1551 (41) - - 
NSPHS06 Sweden 495 55% 51.4 (19.1) 71.9 (12.8) 164 (10) 495 96 (21) - - - - 
RSI Netherlands 1615 54% 66.5 (8.2) 74.3 (11.8) 169 (9) 1615 112 (13) 1615 1525 (37) - - 
SHIP Germany 1198 54% 58.0 (13.5) 80.2 (15.8) 168 (9) 1198 115 (15) 1198 1565 (35) - - 
SHIP-TREND Germany 687 56% 50.8 (13.6) 78.7 (15.1) 170 (9) 687 116 (14) 687 1571 (33) - - 
TWINSUK1 UK 1701 100% 46.2 (12.1) 65.8 (12.5) 163 (6) 1701 76 (18) 1701 1658 (49) - - 
TWINSUK23 UK 1975 100% 46.9 (12.5) 66.1 (12.2) 163 (6) 1975 76 (18) 1975 1653 (50) - - 
H2SS Korea 1753 53% 60.8 (6.6) 61.9 (10.0) 158 (8) - - 1753 1591 (45) - - 
AGES Iceland 3179 58% 76.4 (5.4) 75.8 (14.3) 167 (9) - - - - 3179 0.491 (0.152) 
CroatiaKorcula Croatia 878 64% 56.3 (14.2) 79.0 (14.2) 168 (9) - - - - 878 0.443 (0.098) 
CroatiaSplit Croatia 499 57% 49.3 (14.7) 80.6 (16.3) 172 (9) - - - - 499 0.459 (0.101) 
Subtotal  20569 66% 60.3 (11) 73.3 (14.1) 165 (9) 14260 86 (18) 15514 1593 (42) 4556 0.478 (0.138) 
Insilico replication                
AOGC‡ Australia/UK* 1955 100% 69.6 (8.6) 69.6 (17.3) 158 (16) - - - - - - 
B-PROOF Netherlands 1092 59% 74.0 (6.7) 76.0 (12.4) 168 (9) 1092 69 (17) 1091 1535 (32) - - 
HABC USA 1493 48% 74.8 (2.9) 73.8 (14.3) 167 (9) 1493 73 (18) 1493 1541 (30) - - 
MICROS Italy 588 45% 46 (16.6)  70.2 (14.9)   167 (9) 588 73 (16)  588 1544 (29)  - - 
MrOS-USA USA 3925 0% 73.9 (5.9) 83.1 (12.7) 175 (7) 3925 79 (17) 3925 1551 (30) - - 
SOF USA 2103 100% 80.1 (4.2) 66.3 (12.5) 158 (6) 2103 59 (17) 2103 1527 (30) - - 
YFS Finland 1265 58% 37.9 (5.0) 75.8 (15.5) 172 (9) 1265 80 (16) 1265 1559 (29) 1250 0.560 (0.110) 
HCS-AUS Australia 986 49% 66.2 (7.6) 79.4 (15.5) 166 (9) - - - - 986 0.538 (0.166) 
Subtotal  13407 52% 69.2 (6.9) 75.4 (14.2) 167 (9) 10466 73 (17) 10465 1544 (30) 2236 0.550 (0.138) 
Denovo replication                
AUSTRIOS-B Austria 448 85% 83.6 (5.9) 62.0 (12.3) 156 (8) 448 90 (17) 448 1496 (36) - - 
CABRIO-C Spain 1274 62% 62.4 (9.2) 73.7 (13.1) 161 (8) 1274 70 (23) 1273 1545 (41) - - 
CAIFOS Australia 1113 100% 80.0 (2.6) 67.5 (12.1) 157 (6) 1113 101 (9) 1113 1516 (28) - - 
CALEX-FAM Finland 983 79% 37.0 (22.4) 64.3 (16.9) 164 (11) 983 83 (16) - - - - 
EMAS Europe* 2870 0% 59.9 (11.0) 83.1 (13.6) 173 (7) 2870 80 (19) 2870 1550 (34) - - 
EPICNOR UK 5723 54% 63.6 (9.2) 73.2 (12.4) 167 (9) 5723 79 (20) 5718 1638 (43) - - 
EPOLOS Poland 684 56% 53.4 (16.0) 73.2 (13.7) 166 (10) 684 112 (13) 684 1548 (35) - - 
FLOS Italy 1000 84% 59.8 (12.7) 64.8 (12.3) 163 (9) 1000 58 (7) 1000 1503 (83) - - 
GEOS Canada 5495 100% 55.8 (10.3) 65.4 (11.9) 158 (6) 5495 111 (10) 5495 1546 (32) - - 
LASA Netherlands 894 51% 75.6 (6.5) 74.2 (12.6) 166 (9) 894 71 (20) 894 1611 (44) - - 
MrOS-SWE Sweden 1718 0% 75.4 (3.2) 80.6 (12.0) 175 (7) 1718 81 (21) 1718 1555 (38) - - 
OPRA Sweden 821 100% 75.2 (0.1) 67.6 (11.3) 160 (6) 821 102 (10) 821 1523 (27) - - 
OSTEOSII Greece 307 87% 50.5 (12.6) 74.1 (15.7) 163 (7) 307 112 (16) 307 1556 (36) - - 
PEAK25 Sweden 857 100% 25.5 (0.2) 64.5 (11.2) 168 (6) 857 118 (11) 857 1575 (32) - - 
SWS UK 715 100% 29.7 (3.7) 72.4 (14.8) 163 (7) 714 72 (13) 715 1548 (27) - - 
Subtotal  24902 64% 60.2 (10) 71.6 (12.7) 165 (8) 24901 89 (16) 23913 1568 (40) - - 
TOTAL  58878 62% 62.3 (9.7) 73 (13.6) 165 (8) 49627 85 (17) 49892 1570 (39) 6792 0.502 (0.138) 
‡ The AOGC cohort contributed to insilico lookups of SNP-fracture associations only. * The EMAS study comprised cohorts in Belgium, Estonia, Hungary, Italy, Poland, Spain, Sweden, and UK. 
  
 26 
Table 2. Summary of P-values for association of SNPs in 25 loci with heel BUA, VOS, or heel DXA BMD in GWAS discovery/replication meta-analysis. P-values 
smaller than the genome-wide significance threshold (P < 5x10-8) or suggestive significance threshold (P < 5x10-6) are indicated in bold typeface‡. 
 
    Discovery P-values†  Replication P-values†  Combined P-values† 
Locus SNP Closest gene Genetic function BUA VOS DXA  BUA VOS DXA  BUA VOS DXA 
Combined p < 5 x10-8  9 cohorts, 14258 participants  21 cohorts, 35082 participants  30 cohorts, 49335 participants 
2p16.2 rs11898505 SPTBN1 Intronic, Regulatory region 7.78E-08 2.92E-08 7.68E-01  6.66E-12 1.10E-04 9.63E-02  4.24E-13 6.25E-06 2.65E-01 
6q22.33 rs7741021 RSPO3 Intronic, Regulatory region 8.52E-07 1.72E-07 7.69E-06  1.19E-18 2.54E-21 1.49E-03  9.26E-21 9.58E-20 4.11E-08 
6q25.1 rs4869739 CCDC170 Intronic 5.25E-10 4.75E-11 7.73E-10  1.02E-03 3.92E-08 3.82E-01  1.93E-09 2.64E-18 1.21E-02 
6q25.1 rs3020331* ESR1 Intronic 1.27E-02 7.94E-06 2.01E-04  3.04E-10 3.79E-17 1.95E-01  2.91E-09 6.64E-15 1.26E-03 
6q25.1 rs2982552 ESR1 Intronic, Regulatory region 2.87E-02 3.31E-06 3.83E-04  6.16E-17 1.14E-18 1.00E-01  1.70E-10 7.32E-16 1.21E-04 
7q31.31 rs2908007 WNT16 Upstream 8.59E-21 5.02E-23 4.31E-11  1.31E-22 2.06E-39 3.47E-02  4.32E-35 1.62E-59 1.34E-09 
10q21.1 rs7902708 MBL2/DKK1 Intronic 8.23E-03 1.46E-07 9.51E-01  1.02E-08 6.99E-09 2.60E-03  1.30E-08 5.29E-15 2.47E-01 
11q14.2 rs597319 TMEM135 Intronic 2.62E-04 1.18E-08 5.05E-03  2.01E-12 2.70E-17 2.20E-02  8.23E-14 4.86E-26 3.05E-04 
19q13.11 rs10416265 GPATCH1 Non-synonymous coding 8.30E-07 2.99E-08 1.15E-01  5.84E-08 2.92E-05 3.45E-01  2.37E-13 4.08E-12 6.72E-02 
               
Combined p ≥ 5 x10-8  9 cohorts, 14258 participants  21 cohorts, 35082 participants  30 cohorts, 49335 participants 
5p13.3 rs9292469 NPR3 Upstream 3.09E-06 6.01E-03 9.27E-01  5.95E-01 1.69E-01 9.96E-01  1.43E-01 6.12E-01 9.42E-01 
7p15.2 rs11520772 TAX1BP1 Intronic 9.71E-07 4.84E-04 6.24E-01  8.43E-02 1.32E-01 5.48E-01  2.86E-04 7.07E-03 8.79E-01 
7p14.1 rs6974574* EPDR1 Upstream 5.81E-03 1.34E-05 2.56E-04  2.51E-04 4.84E-03 7.31E-01  8.25E-05 3.89E-05 9.25E-03 
7q11.23 rs38664 UPK3B Intronic 9.10E-04 1.52E-06 6.60E-01  4.39E-02 1.58E-02 5.35E-01  3.25E-04 1.02E-07 8.79E-01 
13q12.3 rs3000634 USPL1 Upstream 2.10E-05 1.27E-07 2.18E-01  6.80E-03 1.91E-01 5.38E-01  8.12E-01 8.00E-02 1.70E-01 
13q14.11 rs9533090 AKAP11 Upstream 3.78E-02 5.04E-03 5.05E-10  7.60E-03 2.44E-04 6.44E-01  1.02E-03 1.40E-05 6.97E-03 
16q24.1 rs7188801 FOXL1 Upstream 3.32E-04 3.09E-06 2.16E-02  3.91E-01 1.66E-02 5.48E-01  9.70E-03 7.62E-06 2.90E-02 
    9 cohorts, 14258 participants  6 cohorts, 10466 participants  15 cohorts, 24723 participants 
2p21 rs17032452 CAMKMT Intronic 8.73E-01 5.30E-01 1.74E-06  5.49E-01 4.24E-01 3.59E-01  6.26E-01 9.67E-01 1.56E-03 
3p14.2 rs6414591 C3orf67 Upstream 3.49E-01 2.39E-01 1.72E-06  1.31E-01 9.13E-02 6.83E-01  7.86E-01 8.17E-01 9.22E-02 
5q31.2 rs11959305 TGFBI Intronic 1.89E-02 1.82E-02 6.84E-08  6.52E-01 2.80E-01 8.61E-01  8.47E-02 7.74E-03 1.15E-01 
7p15.3 rs7787266 STEAP1B Intronic 4.08E-01 4.93E-01 2.53E-06  2.93E-01 3.14E-01 6.21E-01  1.97E-01 2.70E-01 9.71E-03 
9q21.33 rs10868487 GAS1  Downstream 6.10E-01 3.81E-01 2.37E-06  2.61E-01 2.50E-01 7.03E-01  8.57E-01 7.46E-01 8.92E-02 
13q31.1 rs9574655 SPRY2 Downstream 2.58E-01 1.38E-01 9.09E-08  8.59E-01 6.43E-01 8.67E-02  5.81E-01 4.72E-01 3.50E-01 
16q12.2 rs923220 IRX5 Upstream 1.24E-03 7.98E-03 6.05E-07  7.85E-01 7.28E-01 9.34E-01  2.58E-02 3.95E-02 1.56E-02 
20q11.22 rs3746429 EDEM2 Missense variant 4.42E-01 8.27E-01 3.80E-07  2.07E-01 9.14E-02 3.35E-01  7.23E-01 3.93E-01 4.35E-04 
21q22.2 rs2836789 FLJ45139  Upstream 1.56E-01 1.36E-02 1.51E-06   2.09E-03 4.09E-02 5.07E-01   3.77E-03 2.27E-03 1.57E-03 
‡ The P-values in the GWAS discovery are based on a fixed effect meta-analysis model, while those in the replication and combined analyses are based on a random effects meta-analysis model. 
* Secondary signals at the discovery phase following conditional analyses within the region (see Supplementary Figure 6 for the regional association plots). 
† The number of cohorts and participants contributing to the analysis of each SNP at each stage slightly varied depending on quality control filters as well as successful imputation or denovo genotyping of 
the particular SNP. Figure 1 and Supplementary Figure 3 show the exact numbers that were available for each SNP at each stage for the confirmed loci.  
The novel locus is italicized.  
 
 27
Figure 1. Flow chart summarising key features of the discovery and replication phases. 
 
 
 
 
 
Discovery (Part I)
GWAS meta-analysis of 11 cohorts 
• 42 loci with SNPs attaining p < 5 x10-6 considered for further 
regional conditional meta-analysis to select independent 
SNPs for replication. 
Discovery (Part II)
Regional conditional meta-analysis in 9 cohorts (7 of the above cohorts and 
2 new cohorts) and final meta-analysis of the unconditional estimates from 
all 13 discovery cohorts  
• 25 SNPs selected for replication, comprising 23 SNPs with p < 5 x10-6 and 2 
secondary signals at 6q25.1 and 7p14.1 (Table 2). 
• 15 SNPs were primarily associated with BUA or VOS (Table 2). 
• 12 SNPs were primarily associated with HDXA (Table 2). 
Replication
• Insilico lookups for all 25 SNPs in 7 cohorts with QUS data and GWAS. 
• 7 SNPs were in high to moderate LD with SNPs previously denovo genotyped in 
GEFOS/GENOMOS for replication of associations with central DXA BMD (r2>0.8 for 
6 SNPs, and r2>0.6 for 1 SNP), hence were used as proxy SNPs in current effort. 
• 9 SNPs were centrally denovo genotyped in 15 GEFOS/GENOMOS cohorts. 
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Figure 2. Summary of SNP associations with heel BUA or VOS in GWAS discovery meta-analysis and replication in independent samples of participants. 
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The pooled estimates in the GWAS discovery are based on a fixed effect meta-analysis model, while those in the replication and combined analyses are based on a random effects meta-analysis model. 
Allele b indicates the effect allele, and the presence of two alleles in this column indicates that a proxy SNP with r2 > 0.8 (except for 16q24.1 locus for which r2 = 0.6) was used for the replication analyses.  
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Figure 3. Regional association plots for chromosome 6q25.1 region with heel BUA, VOS, and heel DXA 
BMD in discovery cohorts before and after conditioning on the most significant SNP in the region* as well as 
a novel locus for heel bone properties at 11q14.2. 
 
 
 
* The conditional analyses led to the identification of the highlighted secondary signal for association of 6q25.1 with VOS. Conditional 
analyses results for heel DXA BMD were not available from the 3 relevant discovery cohorts. Colour versions of the above figures have 
been made available in the online supplementary materials (Supplementary Figure 6). 
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Figure 4. Comparison of magnitudes of associations of 25 SNPs with heel bone properties and central DXA 
BMD. 
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The SNP associations with central DXA BMD are based on lookup of previously published results from GEFOS. 
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Figure 5. Per allele odds ratios for association with fracture risk for 10 SNPs that were associated with heel 
BUA, VOS, or heel DXA BMD at p < 5 x 10-6 in combined meta-analyses using a random effects model. 
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The pooled estimates are based on a random effects meta-analysis model. FXANY = Any fracture; FXNONVERT = Non-vertebral 
fracture; FXVERT = Vertebral fracture. 
Allele b indicates the effect allele, and the presence of two alleles in this column indicates that a proxy SNP with r2 > 0.8 was used for 
the replication analyses.  
 
